 |
|
|
| |
OPTIMIZE Trial: Noninferiority of Twice-daily Telaprevir Versus Administration Every 8 Hours inTreatment-naïve, Genotype 1 HCV-infected Patients
|
| |
| |
Reported by Jules Levin
AASLD Boston 2012 Nov 10-14
Maria Buti,1 Kosh Agarwal,2 Yves Horsmans,3 William Sievert,4 Ewa Janczewska,5 Stefan Zeuzem,6 Lisa Nyberg,7 Robert S Brown Jr,8 Christophe Hezode,9 Mario Rizzetto,10 Raymundo Parana,11 Sandra De Meyer,12 Donghan Luo,13 James Witek13
1Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain; 2Kings College Hospital, London, UK; 3Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium; 4Monash Medical Centre and Monash University, Melbourne, Australia; 5Outpatients Clinic for Hepatology, Myslowice, Poland; 6Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 7Kaiser Permanente, San Diego, CA, USA; 8Columbia University College of Physicians and Surgeons, New York, NY, USA; 9Hôpital Henri Mondor, Creteil, France; 10University of Torino, Torino, Italy; 11University Hospital of Bahia, Bahia, Brazil; 12Janssen Infectious Diseases BVBA, Beerse, Belgium; 13Janssen Research & Development LLC, Titusville, NJ, USA
|
| |
|
|
|
|
|
